---
title: "Fennec Announces Results of Annual Meeting | FENC Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289374711.md"
description: "Fennec Pharmaceuticals Inc. announced the results of its Annual General and Special Meeting of Shareholders held on June 10, 2025. All nominated directors were elected with high approval rates. Shareholders also approved the appointment of Haskell & White LLP as auditors, executive compensation, and amendments to the 2020 Equity Incentive Plan."
datetime: "2026-06-10T12:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289374711.md)
  - [en](https://longbridge.com/en/news/289374711.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289374711.md)
---

# Fennec Announces Results of Annual Meeting | FENC Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.

Detailed results of the vote for the election of directors are set out below:

**Name of Nominee**

**Votes For**

**% Votes For**

**Votes Withheld**

**% Votes Withheld**

Dr. Khalid Islam

13,858,131

97.84

%

304,760

2.15

%

Mr. Chris A. Rallis

13,808,792

97.49

%

354,099

2.50

%

Mr. Marco Brughera

13,807,501

97.49

%

355,390

2.50

%

Dr. Jodi Cook

13,259,894

93.62

%

902,997

6.37

%

Mr. Jeff Hackman

13,495,309

95.28

%

667,582

4.71

%

  
Shareholders voted 99.64% in favor of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 85.50% in favor of the compensation paid to the Company’s named executive officers, and 91.27% (88.01% after subtracting shares held by insiders eligible to participate in the Company’s 2020 Equity Incentive Plan) in favor of certain amendment to the Company’s 2020 Equity Incentive Plan.

The Company has relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, in the approval of the amendments to its 2020 Equity Incentive Plan.

**For further information, please contact:**

Robert Andrade  
Chief Financial Officer  
Fennec Pharmaceuticals Inc.  
Tel: 919-246-5299

### Related Stocks

- [FENC.US](https://longbridge.com/en/quote/FENC.US.md)

## Related News & Research

- [Adherex Technologies (NASDAQ:FENC) Announces Earnings Results](https://longbridge.com/en/news/280330169.md)
- [Entergy announces quarterly dividend payment to shareholders | ETR Stock News](https://longbridge.com/en/news/294543664.md)
- [Ontex special general shareholders’ meeting: all resolutions approved  | ONXYY Stock News](https://longbridge.com/en/news/294179706.md)
- [MCN Adjourns Special Meeting of Shareholders Until August 26, 2026 | MCN Stock News](https://longbridge.com/en/news/294516088.md)
- [Shareholders Overwhelmingly Approve Transaction with Thoma Bravo | KSIOF Stock News](https://longbridge.com/en/news/294388869.md)